Drug Trial Radar · NCT04236778
First-in-human Study of VE303 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Nov 28, 2017
Primary completion
Mar 11, 2019
Study completion Mar 11, 2019
Sponsor
- Lead sponsor
- Vedanta Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was designed to evaluate safety and tolerability of a range of doses of VE303 in healthy adult volunteers. The study also evaluated pharmacokinetics of intestinal colonization by the VE303 strains and pharmacodynamics of recovery of the gut microbiota after administration of antibiotics followed by a course of VE303.
Conditions
- Healthy Volunteers
Interventions
VE303Drug
The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
Oral VancomycinDrug
Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of VE303 measured by incidence adverse events (AEs)Time frame: 12 months post-dose
- Tolerability of VE303 using modified PROMIS questionnaire (v1.0)Time frame: 12 months post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.